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enrollment after the index date. Medication possession ratio
(MPR) was calculated as the ratio of total days supply of statins
to the total days during the ﬁrst year after the index date (initial
use period). Statin noncompliance was deﬁned as having a MPR
less than 80%. The outcome was hospitalization during the year
following the initial use period. Association of statin noncom-
pliance in the initial use period to subsequent hospitalization was
examined by multiple logistic regression, controlling for age,
gender, region, comorbidity, prior hospital admission and
number of drug therapeutic classes in the initial use period.
RESULTS: A total of 3063 subjects met the inclusion criteria and
were included in the analysis. A total of 1170 (38.2%) had a
MPR less than 80% in the initial use period. Compared with
patients who were compliant to statins, noncompliant patients
were about 40% more likely to have a subsequent hospitaliza-
tion (OR: 1.37; 95% CI, 1.13–1.65). Other factors associated
with signiﬁcantly higher risk of subsequent hospitalization
included female gender, older age, higher Charlson comorbidity
index score, higher number of drug therapeutic classes, and prior
hospitalization in the use period. CONCLUSIONS: Statin non-
compliance in the year after CHD hospitalization was common
among new statin users and associated with higher risk of sub-
sequent hospitalization. These ﬁndings suggest that interventions
to improve compliance could reduce risk for hospitalization.
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OBJECTIVE: To identify key drivers of non-persistence on
therapy, using multivariate regression techniques, based on IMS
Disease Analyzer Germany (DA) data. METHODS: DA is a lon-
gitudinal patient database containing de-identiﬁed patient
records collected from 400 practices (290 GPs and 110 Internal
Specialists) treating currently +/-1.3 million patients. We identi-
ﬁed a cohort of hypertensive patients being prescribed valsartan,
metoprolol, ramipril, enalapril, lisonopril, amlodipine or
hydrochlorothiazide (HCTZ), within the period 2003–2004.
Patients had at least 12 months of data prior to, and following
their index date (date of ﬁrst prescription of the study drug
within the window). History of hypertension was deﬁned as the
difference between diagnosis date and index date. Patients who
start on monotherapy of study drugs and those who start on
combination therapy involving at least one of the study drugs
were analyzed separately. Medication persistence was deﬁned as
the total time on a drug, from initiation of therapy to the end of
the last supplied prescription for that drug without intervening
discontinuation. RESULTS: A total of 42,991 patients were
analysed, of whom 61.7% discontinued study medication within
12 months post-index. Cox-regression showed that heart failure
(Hazard Rate to discontinue therapy; HR = 1.04), renal disease
(HR = 1.072), and not being treated with valsartan (HR = 1.07
to 1.359) independently and signiﬁcantly increased the proba-
bility of being non-persistent. Older age (HR = 0.998 per year),
male gender (HR = 0.948), >6mo history of hypertension (HR
= 0.87), dyslipidemia (HR = 0.96), recent stroke (HR = 0.891),
and receiving combination therapy (HR = 0.92) were signiﬁ-
cantly associated with improved persistence. CONCLUSION:
Different demographic and clinical factors are independently
associated with persistence to antihypertensive therapy. Patients
on valsartan were 7 to 36% more likely to persist compared to
patients taking other frequently used antihypertensive medica-
tions. Considering such factors is important to identify patients
most likely to discontinue therapy and to avoid achieving sub-
optimal therapeutic outcomes.
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OBJECTIVES: To compare several adherence metrics across dif-
ferent therapeutic conditions, which might complicate these
associations. METHODS: Plan participants dispensed lipid low-
ering, antihypertensive, or selective serotonin reuptake inhibitor
between January 1, and June 30, 2004, had their same class pre-
scriptions extracted for six months before and one year after
their ﬁrst prescription from a large deidentiﬁed US prescription
database. Lipid-lowering (n = 102,067), antihypertensive (n =
139,333), and SSRIs (n = 99,439) plan participants without a
same-class prescription in the pre-period had: number of 
prescriptions—prescription count adjusting 3–1 for mail-retail;
persistent period—ﬁrst minus last ﬁll date; length of exposure—
persistent period plus days supply on last prescription; total
days—sum of all days supply; unique days—sum of days with
exposure to drug; medication possession ratio—sum of days
supply divided by length of exposure (variable) or study period
(ﬁxed); proportion of unique days—sum of days with exposure
divided by length of exposure (variable) or study period (ﬁxed);
and continuous days—days spanned before a break in therapy
calculated over the post-period. Results for these adherence
metrics were divided into equal parts for comparisons.
RESULTS: The measures were grouped into: 1) MPR variable
and PUD variable, 2) unique days 3) MPR ﬁxed, PUD ﬁxed, total
days, length of exposure, and number of prescriptions; 4) per-
sistent period; 5) continuous days. Differences among the groups
started within the ﬁrst 30 days, with group 1 having values less
than 1 percent and the continuous group having more than 20%.
Groups 1 and 2 remained lower than the other groups ending at
about 50% while the others ended at about 70%. CONCLU-
SIONS: Differences in how adherence is calculated needs to be
considered when estimating beneﬁts. Other metrics that account
for dose changes, concomitancy, and other complex regimens
may need further exploration.
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OBJECTIVE: Niacin is highly effective in raising HDL-C, while
lowering LDL-C and triglycerides. However, niacin induced
cutaneous ﬂushing may limit patient acceptance. We compared
the persistency with newly-initiated ER niacin versus other lipid
modifying drug (LMD) classes in recent clinical practice.
METHODS: Administrative claims from the Ingenix Lab/Rx
DatabaseTM were used to identify patients aged >20 years who
were new users (i.e. no prescription from the same LMD class
in the pervious 1-year) of statins, ER niacin, ﬁbrates, bile acid
sequestrants (BAS), or ezetimibe between January 1, 2001 and
June 30, 2003 and were continuously enrolled for 1 year after
LMD initiation. The proportion of days covered (PDC) with
each LMD class was calculated in each quarter (1Q–4Q) and
over the 1-year period after therapy initiation. Patients were
deﬁned as persistent if PDC >= 80%. Generalized linear models
